Anafranil is used mainly for obsessive-compulsive disorder and selected depressive disorders. Its active ingredient, clomipramine, increases the availability of serotonin and noradrenaline between nerve cells by slowing their reuptake.
Anafranil belongs to the tricyclic antidepressant class. It is used mainly for obsessive-compulsive disorder, while clinicians may also prescribe it for selected depressive disorders and other conditions when its pharmacological profile is appropriate.
The medicine increases the availability of serotonin and noradrenaline between nerve cells by slowing their reuptake. Serotonin-related effects are especially relevant to obsessive thoughts and compulsive rituals.
Anafranil contains the active ingredient clomipramine and belongs to the tricyclic antidepressant class. Clomipramine increases the availability of serotonin and noradrenaline between nerve cells by slowing their reuptake.
Anafranil tablets are taken by mouth. The exact amount and frequency depend on the purpose of treatment and are agreed with a doctor or pharmacist.
How much Anafranil to use and how often depends on the purpose of use and is agreed with a doctor or pharmacist. The medicine should be taken exactly according to that plan.
Key administration points include:
A missed dose can be handled differently when the next dose is due soon, when several doses have been missed, or when withdrawal symptoms appear. In those situations, the prescriber or pharmacist should provide the next step based on the individual schedule.
Anafranil should not be stopped abruptly after prolonged treatment. Sudden discontinuation may cause nausea, sweating, headache, sleep disturbance, dizziness, irritability, or a return of the original symptoms. A gradual reduction is commonly used when treatment needs to end [1].
This medication is not for you if:
Monoamine oxidase inhibitors can interact dangerously with tricyclic antidepressants. A suitable washout interval is required, and the exact interval depends on the medicines involved.
Other medicines can also increase risk. These include serotonergic antidepressants, certain migraine medicines, tramadol and related opioids, medicines that prolong the QT interval, sedatives, anticholinergic drugs, and medicines that alter liver enzymes responsible for drug metabolism.
Anafranil may increase the effects of alcohol, sedatives, and some antihistamines. It may also affect heart rhythm when combined with other medicines that prolong cardiac repolarisation. The WHO identifies serotonin toxicity as a clinical emergency involving symptoms such as agitation, sweating, tremor, diarrhoea, fever, muscle rigidity, and altered consciousness [4].
Pregnancy and breastfeeding require an individual benefit-risk assessment. Anafranil can cross the placenta and may expose a newborn to adaptation symptoms after late-pregnancy use. Breastfeeding decisions depend on the treatment plan, infant age, and clinical need.
Anafranil may not be suitable if you have heart rhythm or conduction problems, seizures, glaucoma, urinary retention, severe liver disease, or a serious allergy to clomipramine or related medicines. It may also be unsafe if you take or have recently stopped a monoamine oxidase inhibitor, or if you combine it with medicines, alcohol, or supplements that increase sedation, serotonin effects, or heart-rhythm risks. Pregnancy and breastfeeding should be discussed with a clinician before treatment.
Anafranil may cause side effects because it affects several neurotransmitter systems, not only serotonin and noradrenaline. The most familiar effects are anticholinergic symptoms and changes in alertness.
Commonly reported effects include:
Dry mouth can increase the risk of dental problems when it persists. Regular water intake, sugar-free gum, and careful dental hygiene may help. Constipation may improve with adequate fluid intake, dietary fibre, and suitable physical activity when medically appropriate.
Sedation can affect driving, operating machinery, and work requiring sustained attention. Alcohol may intensify this effect. Dizziness on standing can also increase the risk of falls, especially in older adults.
Serious symptoms require prompt medical attention. These include fainting, a rapid or irregular heartbeat, chest pain, severe confusion, seizures, severe allergic swelling, inability to urinate, marked eye pain with visual disturbance, or severe agitation with fever and muscle rigidity.
Antidepressant treatment can also be associated with new suicidal thoughts, worsening agitation, or unusual behavioural changes, especially after starting treatment or changing the dose. Family members may notice changes before the patient does. These symptoms require urgent clinical assessment.
The FDA prescribing information describes cardiac conduction problems, seizure risk, anticholinergic effects, and interactions with medicines that influence serotonin or cardiac rhythm [3].
It is used mainly for obsessive-compulsive disorder, while clinicians may also prescribe it for selected depressive disorders and other conditions when its pharmacological profile is appropriate.
Anafranil is one pharmacological option for obsessive-compulsive symptoms. The choice depends on symptom severity, previous response, side effects, coexisting illnesses, and whether psychological treatment is available.
| Approach | Main therapeutic focus | Limitation |
|---|---|---|
| Anafranil and related tricyclic treatment | Serotonin and noradrenaline reuptake inhibition | Anticholinergic and cardiovascular effects can limit use |
| SSRI-based treatment | Serotonin reuptake inhibition | Nausea, sleep changes, and sexual dysfunction may occur |
| Exposure and response prevention therapy | Gradual reduction of compulsive responses | Requires regular participation and trained therapeutic support |
For obsessive-compulsive disorder, exposure and response prevention can be used alone in some cases or alongside medication. NICE guidance recognises both psychological and pharmacological strategies, with treatment selection based on severity and patient circumstances [2].
Anafranil may be considered when a previous approach has not provided enough relief or when its clinical profile fits the patient. Its drawbacks include a greater burden of dry mouth, constipation, blurred vision, urinary difficulty, sedation, and heart-related effects compared with some newer antidepressant approaches.
Several practical mistakes can reduce benefit or increase side effects:
One detail patients often miss is that blurred vision can make night driving unsafe even when daytime vision seems acceptable. Another is that constipation may become serious when combined with other medicines that slow bowel movement.
In clinical practice, doctors usually set expectations before treatment begins. Anafranil is not expected to remove obsessive thoughts after one tablet. Early effects may include sleepiness or dry mouth, while improvement in compulsions and intrusive thoughts can take longer.
A psychiatrist may begin with a cautious regimen and adjust it after reviewing tolerability, symptom change, sleep, anxiety, blood pressure, and heart-related symptoms. Older adults often need closer monitoring because anticholinergic effects, dizziness, confusion, constipation, and urinary problems can be more pronounced.
For obsessive-compulsive disorder, medication works best when the patient can track meaningful changes rather than relying on a single good or bad day. Useful markers include time spent performing rituals, avoidance of feared situations, distress intensity, and ability to complete ordinary tasks.
A treatment review is needed when there is no meaningful change after an appropriate trial, when side effects interfere with daily life, or when symptoms worsen. Switching or tapering should be planned rather than managed through skipped tablets.
Take the missed dose when remembered unless the next scheduled dose is close. If the next dose is due soon, skip the missed dose and continue with the normal schedule. Do not take two doses together. The FDA medication guidance from 2023 supports avoiding dose doubling after a missed dose, while repeated missed doses should be discussed with the prescribing team.
Some effects, such as sleepiness or dry mouth, may appear early, while improvement in obsessive-compulsive or depressive symptoms usually takes longer. A meaningful response may require several weeks of consistent treatment. NICE clinical guidance published in 2022 describes antidepressant response as a process that requires regular review rather than immediate judgment after the first doses .
Use in people under 18 requires specialist assessment because antidepressants may affect mood, behaviour, agitation, and suicidal thinking in younger patients. The indication, treatment duration, and monitoring plan must be defined by a clinician experienced in child and adolescent mental health. WHO guidance from 2023 emphasises close monitoring of young people receiving antidepressant treatment, especially after initiation or dose changes.
Do not increase the amount or stop suddenly without clinical direction. The prescriber may review adherence, the treatment duration, the diagnosis, psychological therapy, other medicines, sleep, substance use, and medical conditions that can affect response. A Cochrane review from 2019 of treatments for obsessive-compulsive disorder supports reviewing both medication and structured psychological treatment when symptoms remain significant [5].
Regular sleep, moderate physical activity, hydration, and a fibre-containing diet may help manage constipation, fatigue, and general treatment tolerance. Alcohol, recreational drugs, irregular sleep, and excessive caffeine can worsen sedation, anxiety, palpitations, or sleep disruption. The plan should also account for other medicines and supplements, since products with sedating or anticholinergic effects can add to Anafranil’s adverse effects. EMA product information from 2024 also advises reviewing concomitant medicines and supplements.
Alcohol can increase drowsiness, dizziness, poor coordination, and impaired judgement. It may also make driving unsafe and can worsen sleep quality or depressive symptoms. Avoiding alcohol is the safer approach during treatment, especially until the individual response to Anafranil is established. FDA prescribing information from 2023 also warns about impairment with alcohol and other central nervous system depressants.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Anafranil is supplied as tablets for oral use. A clinician chooses the regimen according to the diagnosis, previous treatment response, age, other medicines, and medical history.
Different release types of a medicine may behave differently in the body. A standard tablet releases its contents more quickly than a modified-release formulation. A modified-release tablet must not be crushed, chewed, or split unless the prescribing instructions specifically allow it.
| Formulation category | Release pattern | Practical point |
|---|---|---|
| Standard Anafranil tablet | Conventional release | Taken at the prescribed intervals |
| Modified-release clomipramine tablet | Prolonged release | Must be swallowed according to its specific administration instructions |
| Anafranil treatment plan | Individualised schedule | Dose changes require clinical supervision |
The product page identifies Anafranil as pills in tablet form. Strength and schedule should be selected from the prescribed treatment plan rather than adjusted independently.
A common practical error is treating tablets with different release characteristics as interchangeable. They are not automatically equivalent for timing, swallowing, or dose adjustment.
